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It remains unknown how the COVID-19 pandemic has changed neuro-oncology clinical practice, 
training and research efforts.  
Methods 
We performed an international survey of practitioners, scientists, and trainees from 21 neuro-
oncology organizations across 6 continents, April 24–May 17, 2020. We assessed clinical 
practice and research environments; institutional preparedness and support; and perceived 
impact on patients.  
Results 
Of 582 respondents, 258 (45%) were US-based, and 314 (55%) international. 94% participants 
reported changes in their clinical practice. 95% respondents converted at least some practice to 
telemedicine. 10% practitioners felt the need to see patients in person, specifically because of 
billing concerns and pressure from their institutions. 67% practitioners suspended enrollment for 
at least one clinical trial, including 62% suspending phase III trial enrollments. Over 50% 
believed neuro-oncology patients were at increased risk for COVID-19. 71% clinicians feared for 
their own personal safety or that of their families, specifically because of their clinical duties; 
20% had inadequate PPE. While 69% reported increased stress, 44% received no psychosocial 
support from their institutions. 37% had salary reductions and 63% researchers temporarily 
closed their laboratories. However, the pandemic created positive changes in perceived patient 
satisfaction, communication quality, and technology use to deliver care and mediate interactions 













The pandemic has changed treatment schedules and limited investigational treatment options. 
Institutional lack of support created clinician and researcher anxiety. Communication with 
patients was satisfactory. We make recommendations to guide clinical and scientific 


















1. Clinical trial suspension, including phase III trials was a hallmark of the pandemic. 
2. Practitioners and researchers perceive significant personal risk in doing their jobs. 
3. No consensus exists about risks for SARS-CoV-2 infection in neuro-oncology patients. 
 
Importance of the Study 
This is the first international study of the impact of the COVID-19 pandemic on the field of 
neuro-oncology. We observed changes in treatment options for patients with brain and spine 
tumors, as well as burdens on clinicians and researchers. We highlight major challenges in the 
field, including suspension of clinical trials; financial pressures for practitioners to see patients in 
person; and unmet safety concerns and high anxiety of practitioners and scientists. We also 
identified positive outcomes in perceived quality of communication with colleagues, patients and 
families, and reduced travel and expenses for patients. This work serves as a benchmark 














The COVID-19 pandemic has created many challenges for healthcare1. Neuro-oncology, 
which focuses on treating patients with primary and metastatic brain and central nervous system 
(CNS) tumors and neurologic complications of cancer, has faced challenges, particularly in 
maintaining quality patient care and conducting clinical trials and laboratory research.  
The provider pool in neuro-oncology is relatively small. In 2018, there were 2600 
members in the Society for Neuro-Oncology (SNO) database, of which 1040 (40%) were clinical 
members, including physicians, nurses, and nurse practitioners. Equally small numbers of 
neuro-oncologists practice in Europe, Asia, and the rest of the developed world. In the US, 
approximately 25,000 malignant primary brain tumors are diagnosed annually2. There are 
significant differences in incidence by world region, with the highest incidence of malignant brain 
tumors in Northern Europe and Canada, and the lowest in Southeast Asia.  
Gliomas are the most aggressive primary brain tumor, and they make up the majority of 
diagnoses in neuro-oncology. Standard treatment for high grade gliomas includes surgical 
resection; followed by radiation and temozolomide, an alkylating chemotherapy; and more 
recently, adjuvant use of tumor treating fields. Often during the course of care, patients receive 
dexamethasone, which reduces edema; bevacizumab, a monoclonal antibody that reduces 
angiogenesis and edema; and/or lomustine, an alkylating chemotherapy. Radiation, 
temozolomide, and lomustine all commonly cause myelosuppression and lymphopenia3,4. 
Immunotherapy is not approved for primary brain tumors; it remains under investigation and is 
sometimes used as an off-label treatment at the time of tumor recurrence. 
The pandemic has required re-organization of clinic visits, treatment and diagnostic 
testing schedules, and development of new processes managing therapy-related 












centered on how to approach brain tumor patient treatment in resource-limited settings and 
when significant exposure risk to patients and health care providers exists9. These 
recommendations notwithstanding, it remains unknown as to what practically changed during 
the pandemic. The pandemic has also affected medical teams. While physicians and allied 
professionals are accustomed to dealing with stress and dying patients, the burden of these 
new challenges has been unprecedented on professional and personal lives. Clinicians need 
support during the COVID-19 pandemic10, and guidelines exist for managing psychological 
stress and maintaining healthy physical and mental states11. However, we lack basic 
measurements of what clinicians and researchers are experiencing.  
Medical education was restructured so medical students, residents, and fellows may 
continue learning to take care of patients and advance through their training programs12,13. 
Many programs are facing financial challenges that jeopardize the continuity of their training 
mission and the ability to accept new trainees.   
Lastly, scientists in neuro-oncology, attempting to understand the mechanisms 
underlying brain tumor development or identify new treatments, have had to stop or postpone 
costly experiments, and are now at risk of losing funding to continue supporting these efforts 
Here, we sought to address these issues, and evaluate the perceived effects of these 
changes on neuro-oncology patient care. We asked the international community of healthcare 
providers, scientists, and trainees in the field to share their experiences during the pandemic. 
This survey tool is not a method to identify root causes of the problems we identify. This 
framework will guide further studies and recommendations on how to best take care of CNS 
cancer patients, support clinical caregivers, and identify opportunities for institutions to continue 
to advance their research mission. These findings and principles will be broadly applicable to 













The survey (Supplementary File 1) was developed by the SNO COVID-19 task force, 
composed of adult and pediatric oncologists, surgeons, radiation oncologists, laboratory 
scientists and patient advocates. The task force generated a set of general questions for all the 
participants and in addition, we created several pathways based on self-designation [e.g., 
clinician (neuro-oncologist, neurosurgeon, or radiation-oncologist), scientist, trainee (graduate 
students, postdocs, residents, and fellows), social worker, training program director]. 
Participants who were members of more than one group were asked to complete all applicable 
pathways. Topics were selected based on interests of the committee, and included questions 
about personal physical/mental health, institutional response, clinical practice changes, and 
individual career outcomes. Questions were a combination of binary response, multiple choice, 
Likert scale, and free response. For some topics, respondents were asked an overall question 
and then provided follow up binary questions for more detail responses.  The time period for 
which questions were asked was since the beginning of the COVID-19 pandemic in their 
respective countries. The survey was available in English only. We sent email survey invitations 
to members of 21 neuro-oncology organizations (Supplementary File 2) on 6 continents, and 
advertised the survey on multiple social media platforms. The survey was administered through 
Survey Monkey (www.surveymonkey.com) from April 24-May 17, 2020, and contained 134 
questions, presented in modular format with smart logic. We used R 4.0.0 software to generate 
summary statistics and perform statistical analyses. Categorical variables were compared using 
chi-square tests, and continuous variables were compared using t-tests (when only two 
comparison groups) or ANOVA (when more than two comparison groups). Data on sex, age 














A total of 582 responses were received. Respondents were located in the United States 
(258, 45%) and internationally (324, 55%) (Fig. 1). Of international respondents, Europe 
(124/582, 21.3%) and Asia (91/582, 15.6%) were the most represented regions, and within 
these, Spain (37/582, 6.4%) and Japan (19/582 3.3%) were the most common countries of 
residence (Fig. 1). Respondents representing those with direct patient contact included 53.4% 
physicians (311/582), 2.6% nurse practitioners and physician assistants (15/582), 0.7% nurses 
(2/582), and 0.2% social workers (1/582); and 7.9% were researchers (46/582) (Table 1). Of the 
clinicians, 71.0% treated adults (341/582), 11.3% children (54/582), and 17.7% treated both 
(85/582). Within the US, a most clinical practitioners were located at academic centers (79.0% 
of non-researchers, or 452), compared to private practice (15.2% of non-researchers, or 70).  
 
Neuro-oncology relevant risk factors for COVID-19 
Regarding beliefs of COVID-19 risk, 50.3% respondents believed that neuro-oncology 
patients, before any treatment, are at increased risk for contracting the virus (180/487).; 48.9% 
believed steroids increase susceptibility to SARS-CoV-2 infection (173/487), but 43.8% reported 
they were unsure and needed more evidence (155/487). Twenty eight percent believed 
radiotherapy increases infection risk (100/487). Forty six percent believed temozolomide use 
increases susceptibility (165/487), and 21.6% believed that immunotherapy increases risk 
(77/487).  
 
Effects on clinical practice and patients 
The pandemic required changes to clinical practice and clinical trial opportunities, and in 
some cases, clinicians reported pressures related to billing. While practitioners voiced concerns 
about the emotional wellbeing of their patients, there were perceived positive benefits to 












Ninety four percent of participants reported changes in clinical practice due to the 
pandemic (361/386).  The proportion reporting changes was highest in the US (96%, 169/177), 
compared to Europe (95%, 87/92) and Asia (82%, 48/59, p=0.003).  Regarding survival, 44.5% 
thought practice changes due to the pandemic would reduce survival, outside of any direct 
effect of SARS-CoV2 infection in their patients (151/339). This perception was highest in Asia 
(54.0%, 30/53) compared to Europe (45.5%, 35/77) and the US (39.8%, 64/131), but not 
statistically significant (p=0.101). Almost all respondents transitioned to the use of video or 
telephone visits for some aspects of clinical care (95.4%,356/373; Fig. 2). Use of telemedicine 
was slightly lower in Asia (85.2%, 48/56), compared to Europe (97.7%, 86/88) and the US 
(98.3%, 171/174, p=0.001). A majority (56.8%, 192/338) reported this transition was at least 
somewhat difficult, however, 80.1% received adequate information technology support 
(285/351). 
While practitioners greatly used telemedicine, 85.9% (322/375) canceled what they 
deemed non-essential patient visits, and 16.2% moved patient visits at least two months into the 
future (61/376). Of these, 55% sche uling changes were requested by patients or caregivers 
(206/371). Regarding chemotherapy scheduling, 12.3% (35/285) practitioners moved inpatient 
chemotherapy by up to two weeks and another 6.7% moved it out by up to a month (19/285). 
Regarding referrals, 27.2% (101/372) practitioners referred patients to other institutions as a 
result of pandemic pressures, and 65.4%  (233/356) changed MRI schedules for their patients. 
Referrals to other providers were most frequently reported in Asia (43.9, 25/57%), as compared 
to Europe (17.0%, 15/88) or the US (24.4%, 42/172, p=0.002). 
Practitioners remained concerned about emotional and palliative care of patients. 80% 
clinical respondents noticed increased anxiety and depression in their patients. Almost 20% 
respondents noted an increasing need for palliative care consults. Approximately 35% reported 
increased frequency in discussion of end of life issues since the beginning of the pandemic, but 












When asked whether there may be any positive aspects of the pandemic, 88% agreed 
or strongly agreed (415/471) that new technologies applied toward patient care were a positive 
outcome. In fact, 84% (403/474)  agreed or strongly agreed that virtual meetings, including 
tumor boards, were very helpful. Remarkably, 74.3% (347/ 467) of respondents agreed or 
strongly agreed there was increased satisfaction of patients and families, due to decreased 
burdens of spending time and money traveling to appointments. This was highest in the Asia 
(75%, 54/72), compared to Europe (67%, 69/103) and the US (67.9%, 167/226, p= 0.0152). 
59.5% (275/462) practitioners also agreed or strongly agreed  that the quality of care exchange 
would be positively affected by the change in norms during the pandemic. This was highest in 
Asia (63.4%, 45/71), compared to the US (62.2%) or Europe (50.0%, 50/100, p= 0.0044).  
In terms of reimbursement, 25.9% (83/321) respondents stated they were not billing for 
technology-assisted visits. This was highest in Asia (56.8%, 25/44) and Europe (47.3%, 36/76), 
compared to the US (6.9%, 11/160, p<0.001). Overall, 29.4% (94/320) respondents had not 
received effective support in billing for these types of visits. Among those that reported billing for 
telephone and video visits, 82.8% (193/233) reported receiving effective support as compared to 
only 35.5% (27/76) of those that did not bill for telephone and video visits (p<0.001). 
Additionally, nearly 10% (28/322) respondents felt pressured by their institution to do in-person 
visits,  because of billing needs and not because patient care necessitated an in-person visit; 
this pressure was greatest in Asia (15.9%, 7/44), followed by the United States (7.9%, 11/156), 
and then Europe (5.3%, 4/76, p=0.104). 
Notably, 67% practitioners had suspended enrollment for any clinical trial (191/285), with 
50% for phase I trials (99/198), 52% for phase I/II trials (102/193), 53% for phase II trials 
(106/197) and 62% for phase III trials (124/202) (Fig 3).  The effect of COVID19 on non-
therapeutic trials was not measured by this survey, and it is not possible to assess the effect on 
other human subjects research. Regarding changes to treatment, 27.4% (46/168) practitioners 












infusions of bevacizumab  (32/162). 43% (71/165) noted they were being more careful using 
myelotoxic regimens because of unknowns about SARS-CoV-2 infection and those at risk. 9%  
(14/156) practitioners stopped off-label regimens, and 23.1% (36/156) reduced their frequency. 
Pediatric oncologists had not changed their practice in any significant way. 
Twenty eight percent of respondents believed radiotherapy increases susceptibility to 
SARS-CoV2 (100/363). Radiation oncology plans for high-grade glioma were unchanged in 
77.1%  (37/48); 16.7% cases were delayed by 2-4 weeks (8/48). For other indications, less than 
40% of radiation oncology plans remained unchanged (18/48); approximately 58.3% (28/48) 
were delayed by at least two weeks. In cases of modified radiation plans, 68% (17/25) were 
changed to shorter courses with higher daily doses   or shorter courses with a lower total dose 
(20%, 2/25)  (Fig. 4). 
In terms of changes in surgical practice, an average of 60% of elective cases were 
rescheduled into the future, and remarkably, an average of 37% of elective procedures were 
canceled. 14.3% (12/84) cases that were planned with an endonasal approach were converted 
to craniotomy because of guidelines from respective institutions and surgical organizations. 
Notably, in cases where there was inadequate personal protective equipment (PPE), 
approximately 19.5% (16/82) of respondents reported already scheduled surgical procedures 
proceeding at times or very often. 
 
Effects on laboratory research 
Neuro-oncology laboratory-based research significantly slowed during the early months 
of the pandemic. Overall, 63% respondents closed their laboratories (34/54), with the number 
being 78.6% in the US (22/28); 72.7% respondents stopped long-term experiments (32/44). 
Respondents were not asked how long these laboratories were closed. Regarding funding 
prospects, 47.1% (24/51) were “very concerned” about their own research funding because of 












deadlines had been postponed, while 48.7% (19/39) believed pandemic-related changes gave 
them more time to write scientific manuscripts. Nearly 30% of respondents (17/57) reported their 
academic careers would be altered. For the US-based respondents, only 13.3% (2/15) reported 
a visa status was at risk because of pandemic-related pressures or policies; of note, the survey 
was conducted prior to the June 22, 2020 presidential executive order suspending H1B and 
other foreign worker visas. 
 
Work hours, salary, benefits and job security 
While approximately 30% (125/433) respondents reported increased work hours since 
the pandemic started, 37% (160/436) had their salary temporarily reduced. This was higher for 
respondents who primarily treated adults (38%, 107/ 279) as compared to children (23%, 10/43, 
p=0.0016). Of those with salary reductions, 53.6% (74/138) had salaries reduced by at least 
20% . 4% (16/434) respondents had been furloughed or fired. The majority of respondents in 
Asia (58.2%, 39/67) reported salary reduction, as compared to 33.2% US respondents (68/205)  
and 21.6% European respondents (21/97 , p<0.001) (Fig. 5). Thirty seven percent of clinical 
practitioners (85/ 228) and 57% of researchers (4/7) reported a severe or moderate to severe 
fear of loss of job security (p=0.4291). This was higher in private practice (51.1%, 24/47) as 
compared to academic institutions (37%, 87/238), and was highest in the US (46.4%, 65/140), 
compared to Europe (34.5%, 20/58) or Asia (37%, 20/55, p= 0.1303). 
 
Well-being 
The majority of respondents (75.7%, 206/272) reported increased stress during the early 
months of the pandemic. This was higher in the US (82%, 107/130), compared to Asia (61.2%, 
34/52) and Europe (58.8%, 34/52, p=0.190). Regarding personal fears, 81.4% (188/231) 
practitioners had moderate or severe fear for the health of their own families, specifically 












health, specifically because of their research duties. Of all respondents, 53.8% (161/299) had a 
moderate or severe concern about transmitting SARS-CoV-2 to their family, and 37.4% 
(111/297) had moderate or severe concerns about transmitting to other health care workers. 
“Severe concern” about one’s own health and survival was reported in approximately 10% 
(27/298) of all respondents. While a majority faced increased stress, only 56% (242/432) had 
psychosocial support offered by their institution. Institutional psychosocial support availability 
varied significantly by region, with 72% US respondents (147/203) reporting they were offered 
support, compared to 49.5% in Europe (48/97) and 22.4% in Asia (15/67, p<0.001). 
 
Training 
Approximately half of fellowship program directors worried about funding for their fellows 
because of the pandemic (20/38), and 40% (14/35) reported concerns they would not be able to 
completely fill neuro-oncology fellowship slots for 2021.  
 
DISCUSSION AND RECOMMENDATIONS 
There have been several consensus statements and commentaries regarding neuro-
oncology care during the pandemic6,7,14, and analyses of the caregiver, not-for-profit and brain 
tumor charity experiences15,16.  Our international survey provides data that reveal the impact of 
the pandemic on the practice of neuro-oncology care, its effects on clinical caregivers and 
patients, and research (Table 2). First, the clinical practice dramatically changed in the first 
several months of the pandemic. Transition to telemedicine occurred almost universally, 
although it varied by region. The closure of clinical trials, including phase III, was remarkable, 
especially given the poor standard of care options for patients with malignant gliomas. These 
closures may reflect lack of clinical research administrative support due to financial or safety 
concerns; a lack of flexibility in government and pharmaceutical trial contracts; a general lack of 












difficulty obtaining operating room specimens; or other causes. We also wonder whether this 
reflects a feeling among providers that what we have to offer patients in terms of treatment does 
not carry a significant chance of benefit and therefore does not meet a threshold of risk to 
participate. Comparing these findings to other cancers and diseases will be helpful to identify 
the root cause of this problem. A study of Canadian oncologists early in the pandemic similarly 
found that half of respondents reported a cessation of clinical trial accrual17.  Public pressure by 
patient advocacy groups, as well as more institutional experience with how to manage clinical 
trial complexities during crisis, may enable trials to remain open in the future. It was remarkable 
that clinical practitioners believed that patient satisfaction has increased because of improved 
communication and travel reduction. This improved satisfaction may also be due to reduced 
delays in scheduling, which we did not assess. There may be lessons here on how to improve 
care beyond the pandemic and it will be important to analyze patient and caregiver 
assessments to corroborate this perception of the care team. For example, respondents 
deemed virtual platforms beneficial for tumor boards and communication with colleagues and 
this may represent a lasting positive outcome of this pandemic.  In addition, such patient and 
caregiver-facing studies should evaluate whether the usefulness of technology-assisted visits is 
evident across the board, or if the elderly or patients in resource-poor settings who find it more 
difficult to get access to care benefit the most. Lastly, these results provide a platform for future 
outcomes research aimed at assessing whether subsets of virtual care are inferior, non-inferior, 
or superior, than traditional health care delivery in terms of medical outcomes, patient/caregiver 
satisfaction, resource utilization, and financial ramifications to the health care system, families, 
and society. This may also be occasion to revisit the general usefulness of procedures that were 
dropped during the pandemic.  
Next, the degree of practitioners’ worries for their own, and their families’ health because 
of potential exposures they encounter at work is remarkable. It was striking that 15% of surgical 












beneficial, particularly for patients with aggressive tumors. Many of these procedures were 
delayed. The impact on survival remains unknown. 
A large percentage of respondents faced significant financial loss. Further work is 
required to determine the long-term effects of these financial changes on productivity and 
patient outcomes. We also note the significant pressures that exist for clinical practitioners and 
researchers alike that come from the nature of the pandemic itself. For example, institutions 
should take measures to support those with children and elder care giving responsibilities. 
School closures or schools on altered schedules relying on home education, are likely 
disproportionately more challenging for women. We did not assess this, but future studies 
should identify the gender differentials in terms of stress, productivity, and support received. 
Support may come from tenure clock delays, financial support for those with children, and 
technical help in the laboratory.  
Additionally, the future of neuro-oncology research may be in question, as trainees in the 
clinic and the laboratory face challenges with funding and future training opportunities. While the 
economy as a whole is affected by the pandemic, we wonder how much might be lost in terms 
of advances in the field if trainees leave the pool of future neuro-oncology practitioners and 
researchers. 
We recommend hospitals and insurance providers offer support for billing for video and 
telephone visits. Education on Medicare (in the US) and other insurance reimbursement policies 
for telemedi ine use should be improved. Ten percent of respondents felt pressured by their 
institution to continue to see patients in person because of billing considerations. While there 
may be more nuanced reasons for this that our survey did not capture, this compounds stress 
without improving patient care, and clinical societies should advocate toward the end of this 
practice. Beyond the perceived health risks of clinical practitioners and researchers, the degree 












While there are early observations that cancer patients in general may be more 
vulnerable to developing COVID-19,18-23 this is not certain and there remain open questions for 
further research, specifically in the care of patients with brain tumors. There are strongly 
divergent opinions on whether or not having a brain tumor increases the risk of contracting the 
virus and whether or not temozolomide and standard steroid dosing affect susceptibility. 
Retrospective and laboratory-based studies may yield insights. Additionally, comorbidities in the 
brain tumor population, such as venous thrombosis and pulmonary embolism, or pulmonary 
disease in those with Pneumocystis jirovecii, may have ramifications for the susceptibility of this 
patient population to infection with SARS-CoV-2.  
A study of this kind is not without limitations given the fluid nature of the pandemic and 
varied institutional, national, and international responses. Due to the way that the survey was 
advertised, it is not possible to calculate a response rate. The number of total responses 
represent a small proportion of membership in professional organizations that were contacted 
about participation, suggesting that only a small proportion of the neuro-oncology community 
was captured by this survey. The survey was offered only in English, which limited participation 
from non-English speakers. These factors introduce the possibility of selection bias. While we 
were able to capture the burden providers felt related to the angst over uncertainty and the well-
being of their patients, staff, families and themselves, we recognize that women and people of 
diverse backgrounds may have been impacted in ways we did not capture due to the lack of 
inclusion of these demographic variables.  The xenophobia that emerged resulting in  bias faced 
by Asian colleagues and patients reported elsewhere is unprecedented24.  Our study did not 
address  aspects of discriminatory behavior as a result of the COVID-19  pandemic, nor were 
we able to assess the impact of stressors faced by women providers and single parents 














Our work serves as a baseline appraisal of neuro-oncology during the early months of 
the pandemic. Evidence suggests practitioners are at risk for burnout. Clinical trial and off-label 
options are being reduced. Standard treatment options are being modified. New research efforts 
have been slowed. On the other hand, our assessment provides institutions and advocacy 
groups with a framework to intervene. As we all learn more, our hope is that such interventions 
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Figure 1. Number of respondents by A) country and B) US State. 
Figure 2. A) Proportion of respondents reporting increased use of telephone and video visits. B) 
Percentage of cases transferred to video or telephone. C) Primary person requesting change 
(respondents may have selected multiple options). D) Proportion reporting positive patient outcomes as a 
result of these changes. 
Figure 3. A) Proportion of respondents reporting suspending clinical trials overall and by phase. B) 
Proportion of respondents reporting restrictions on performing elective surgeries. C) Outcome of elective 
surgical cases. D) Proportion reporting performing clinical care without appropriate PPE. E) major factors 
guiding decision making for elective surgeries.  
Figure 4. A) Overall proportion of respondents reporting salary reduction and proportion reporting 
reduction by region. B) Amount of salary reduction. 
Figure 5. Proportion of respondents that looked for psychosocial support and who were offered support 















Table 1. Characteristics of Survey Respondents. 
Questions N = 582 
Do you primarily consider yourself a
*
: (%)  
Clinician 227 (39.0%) 
Clinician scientist 174 (29.9%) 
Scientist 39 (6.7%) 
None of the above 5 (0.9%) 
No response 137 (23.5%) 
Occupation (%)  
Physician 311 (53.4%) 
   Neuro-Oncologist (includes medical oncology, neurology or pediatrics) 169 (29.0%) 
   Neurosurgeon 94 (16.2%) 
   Radiation Oncologist 48 (8.2%) 
Scientist or researcher 46 (7.9%) 
 Advanced practice practitioner (nurse practitioner, physician assistant) 15 (2.6%) 
Trainee (includes graduate students, postdocs, residents, and fellows) 11 (1.9%) 
 Nurse 4 (0.7%) 
 Occupational, speech or physical therapist 2 (0.3%) 
Social worker 1 (0.2%) 
Other 13 (2.2%) 
No response 179 (30.8%) 
Do you primarily treat adults or children? (%)  
Adult patients 341 (58.6%) 
Both adult and pediatric patients 85 (14.6%) 
I do not provide direct care to patients 81 (13.9%) 
Pediatric patients 54 (9.3%) 
Neither 11 (1.9%) 
No response 10 (1.7%) 
Where do you primarily practice? (%)  
Academic center (main campus or its satellite locations) 452 (77.7%) 
Private practice 70 (12.0%) 
Other 40 (6.9%) 
No response 20 (3.4%) 
World region (%)  
United States 258 (44.3%) 
Europe 124 (21.3%) 
Asia 91 (15.6%) 
Other 109 (18.7%) 
* 
 This  question was required to move forward with the rest of the survey (Supplementary File 1). If this 













Table 2. Key findings and recommendations for institutions and COVID-19-related research priorities for 




Clinical trial enrollment was impacted by the pandemic. 
In some cases, telemedicine billing support for practitioners was inadequate. 
Some practitioners felt pressure to do in-person visits. 
Elective surgical practice changed. 
Perception of increased anxiety in patients.  
Respondents expressed concerns about their emotional well-being, safety for self and family, and financial impact 
from the pandemic. 
Positive aspects of pandemic-based changes:  
    Technologies applied to patient care 
    Virtual meetings among colleagues 





Modify and prioritize clinical trial infrastructure to ensure access for all patients. 
Provide support for billing education for telephone and video visits. 
Remove pressures on providers to see patients in-person when not clinically necessary. 
Consider support for those with children and elder care responsibilities. 
Provide means of psychological support to staff . 
 
Areas of further research: 
Effects of modified treatment schedules, in-person visit reductions and surgical delays on patient outcomes. 
COVID-19 risk factors and outcomes in neuro-oncology patient population as a function of treatment; laboratory 
studies in disease models. 
Impact of financial changes on productivity and provider wellness. 
Impact of financial changes on conduct of basic science and clinical research. 
Burdens as a function of provider and researcher gender and other demographics. 
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